跳至主要内容
临床试验/NCT03150537
NCT03150537已完成4 期

Comparison of Routine IM Influenza Immunization and Administration by Jet-injector (Med-Jet MIT H4™ & Disposable Cartridge) in Healthy Young Adults

brian.ward2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2017年5月12日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
80
试验地点
2
主要终点
Local and systemic effects will be measured after vaccination

研究概览

简要总结

80 subjects (healthy adults) will be randomized to receive the seasonal flu vaccine either by needle & syringe or by the MIT needle-free injector (Med-Jet MIT H4™ & Disposable Cartridge). The study will be conducted after the normal flu season has passed (ie: March-April). Half of those randomized to standard vaccination (n=20) will receive vaccine drawn from a multi-dose vial while the other half (n=20) will receive vaccine drawn from a single use vial. The same vaccine as the multi-dose vial will be delivered to the other half of the subjects (n=40) using the MIT injector. How long it takes to prepare and deliver the vaccines will be assessed (a time-motion study). Subject acceptance before and after injection will be assessed as well as local and systemic side effects. Standard serologic measures of immune response to flu vaccination (ie: antibodies) will determine whether the Med-Jet H4 injector induces the same kind of immune response as needle & syringe delivery.

详细描述

Eighty healthy adults (18-49 years of age) will be randomized 1:1 to receive:

  • A single dose of trivalent inactivated influenza vaccine (TIV: Fluviral™: 0.5mL IM)

  • Half will receive the vaccine using a pre-filled syringe

  • Half will receive the vaccine using a multi-dose vial

  • Or,the same vaccine delivered IM using the Medical International Technologies Inc. (MIT) compressed air vaccine delivery system (Med-Jet MIT H4 & Disposable Cartridge).

Primary study outcomes will be i) safety (local and systemic reactions) followed for 21 days and ii) immunogenicity at 21 days using the standard serologic assays (eg: hemaggultination inhibition (HI) and microneutralization (MN)).

Secondary outcomes will be time-motion analyses of vaccine preparation and administration to assess possible time-saving associated with Med-Jet H4 delivery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Prevention
盲法
Double (Investigator, Outcomes Assessor)

盲法说明

Observer-blind study

入排标准

年龄范围
18 Years 至 49 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male and female adults
  • 18 to 49 years of age
  • body mass index (BMI) of ≥ 18 kg/m2 and ≤ 32 kg/m2
  • Must be accessible by phone on a consistent basis and be available for the D21 blood draw

排除标准

  • Any influenza vaccine during the 2016-2017 season
  • significant acute or chronic, uncontrolled medical or neuropsychiatric illness
  • confirmed or suspected immunosuppressive condition or immunodeficiency
  • history of autoimmune disease, cancer, or treatment for cancer within 3 years of study vaccine administration
  • Receipt of any investigational or non-registered product within 30 days prior to study enrolment
  • receipt of systemic glucocorticoids at a dose exceeding 10 mg of prednisone per day, or equivalent, for more than 7 consecutive days or for 10 or more days in total within 1 month of vaccine administration
  • any other cytotoxic or immunosuppressant drug or any globulin preparation within 3 months of vaccination
  • blood transfusion within 90 days of study vaccination
  • Although there is no known danger from influenza vaccination during pregnancy, pregnant women will be excluded since the efficacy of the Med-Jet delivery system is not yet known
  • known drug or alcohol abuse will also be excluded.
  • Temporary Contraindications Following the resolution, in the opinion of the Investigator, of the following temporary conditions that constitute contraindications to administration of study vaccine, subjects may be enrolled in the study:
  • Temperature ≥ 38.0 ºC within 24 hours prior to randomization.
  • Acute cold symptoms such as upper respiratory tract infection symptoms, with or without fever, which typically resolve in 48 to 72 hours prior to randomization.

研究组 & 干预措施

Jet injector

Active Comparator

40 participants will receive Fluviral influenza vaccine using the Med-Jet H4

干预措施: Fluviral influenza vaccine (Biological)

IM injection (pre-filled syringe)

Active Comparator

20 participants will receive Fluviral influenza vaccine using pre-filled syringes for time-motion comparison to Med-Jet H4

干预措施: Fluviral influenza vaccine (Biological)

IM injection (multi-dose vial)

Active Comparator

20 participants will receive Fluviral influenza vaccine using a multi-dose vial for time-motion comparison to Med-Jet H4

干预措施: Fluviral influenza vaccine (Biological)

结局指标

主要结局

Local and systemic effects will be measured after vaccination

时间窗: 0 - 21 days

Solicited and unsolicited local and systemic adverse events will be collected between day 0-3 by phone and day 4-21 by diary after influenza vaccine (TIV) delivered by jet-injector or by standard needle.

次要结局

  • Immunogenicity of influenza vaccine given by needle or jet injector(Day 0 (day of immunization) and day 21)
  • Time to administer vaccine by jet-injector or standard needle will be measured(Day 0 (day of immunization))

研究者

发起方
brian.ward
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

brian.ward

MD

McGill University Health Centre/Research Institute of the McGill University Health Centre

研究点 (2)

Loading locations...

相似试验